Questions? Comments? Send us a message!Recent research indicates that GLP-1 receptor agonists, originally developed for diabetes and obesity, show significant potential in treating substance use disorders (SUDs) and serious mental illnesses. Clinical trials and preclinical studies suggest these medications, such as semaglutide and exenatide, can effectively reduce alcohol cravings and consumption by modulating the brain's reward circuitry. Beyond addiction, these drugs may mitigate the metabolic side effects and weight gain associated with antipsychotic treatments for mental health conditions. While evidence is particularly strong for alcohol use disorder, preliminary data also suggest benefits for nicotine and opioid misuse. Despite this promise, widespread clinical adoption faces hurdles regarding insurance reimbursement and the need for larger, long-term studies. Broadening the use of these medications could bridge the gap between metabolic health and neuropsychiatric recovery.Check out simplyherbals.net and tell them Topics in Palliative Medicine sent you!Support the showThank you for your interest in Ethics in Palliative Medicine! Follow us at https://epionepalliative.com and on X: @PallCareEthics

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related